In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

A rumor that pharmaceutical companies behind popular weight-loss and diabetes medications like Ozempic faced lawsuits ...

“The results we got were as good as we can possibly achieve with an oral small molecule GLP-1," says Dr. Dan Skovronsky, Lilly’s chief scientific officer. “The safety, tolerability, and efficacy were ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...

The FDA's decision is a win for Lilly, the drug's manufacturer, according to the Associated Press, prices and ways to access drugs like Zepbound and Mounjaro could be affected as a result of the move.

This quarterly performance by the weight loss portfolio prompted Lilly to boost the company's full-year revenue guidance by $3 billion to the range of $45.4 billion to $46.6 billion.

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

In the three months ended June 30, Eli Lilly's revenue increased 36% year-over-year to $11.3 billion, driven by demand for its weight-loss drugs, Mounjaro and Zepbound, as well as its breast ...

The Food and Drug Administration on Friday approved Eli Lilly 's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, expanding its ...

With strong cash flows derived from a stable and diversified product portfolio, Eli Lilly remains on solid financial footing. We expect the company's debt/EBITDA level to fall from close to 1.9 ...